arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CERO THERAPEUTICS HOLDINGS, INC.

CERO
— Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
22 Visible periods
22 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, CERO THERAPEUTICS HOLDINGS, INC. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 10.0% ↘
FCF / Share $-0.19 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

22-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.89M
↓ -8.7% —
FCF / Share Free cash flow per share
$-0.19
↓ -292.1% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.81x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓
38

Dividend History

Dividend / share · sourced from SEC filings
$10.37 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 6 years · 22 quarters